SphingoTec's biomarker discovery is based on the highest standard of evidence, with over 100 publications, over 100 clinical studies, and more than 100.000 patients enrolled. Browse our scientific publications to learn more about how our biomarkers can impact patient care. You can use filters to narrow your search results by Year, Biomarker and Indications.
2022 penKid pro-ENK Acute Kidney Injury Other
2022 penKid Acute Kidney Injury Other
2022 penKid Acute Kidney Injury Sepsis Other